Abstract
Hepatotoxicity is a common clinical manifestation associated with a wide range of anticancer therapies. Because of the inherent toxicity of anticancer therapies, oncologists must maintain a broad understanding of their effects on the body, including the liver. Therefore, the study was conducted to examine the effects T. terrestris extract on damaged liver as a result of giving cytarabine. In the experiment, twenty-four male rats were employed. The rats divided to four group each group with six rats, lasted about during 28 days the rats were administration as the following groups, which include: group (G1) control negative: control negative: six rats were administered with normal saline, and were euthanized after four weeks, group (G2) of cytarabine (Ara-C 25): in this group six rats will be administrating by cytarabine (Ara-C 25 mg/kg bw) intraperitoneally every day for four weeks is the control positive: in this group six rats will be administered by T. terrestris extract (250 mg/kg body weight) orally for four weeks, group (G3) experimental group: in this group six rats will be administrating by cytarabine (Ara-C 25 mg/kg bw) intraperitoneally + T. terrestris extract (250 mg/kg bw) orally for four weeks, group (G4) is the control positive: in this group six rats will be administered by T. terrestris extract (250 mg/kg body weight) orally for four weeks. The purpose of this study was to evaluate the protective role T. terrestris extract on cytarabine induced hepatotoxicity on liver tissue in male rats.